74205-01-9

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(3-Methoxyphenyl)cyclopropanecarbonitrile is used as an intermediate in the synthesis of pharmaceuticals for its potential applications in the development of new drugs and drug candidates. Its unique structure allows for the creation of various medicinal compounds with different therapeutic properties.
Used in Agrochemical Production:
1-(3-METHOXYPHENYL)CYCLOPROPANECARBONITRILE is also utilized in the production of agrochemicals, contributing to the development of new pesticides, herbicides, and other agricultural chemicals that can improve crop yields and protect plants from pests and diseases.
Used in Organic Compounds Manufacturing:
1-(3-Methoxyphenyl)cyclopropanecarbonitrile serves as a key component in the manufacture of various organic compounds, showcasing its versatility and importance in organic chemistry. Its presence in these compounds can lead to the development of new materials with unique properties and applications.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, 1-(3-Methoxyphenyl)cyclopropanecarbonitrile is used for research purposes, particularly in the exploration of new drug targets and the design of innovative therapeutic agents. Its unique structure and reactivity make it a promising candidate for the development of novel pharmaceuticals with improved efficacy and safety profiles.
Overall, 1-(3-Methoxyphenyl)cyclopropanecarbonitrile has significant industrial and research applications in the field of organic chemistry, making it an essential compound for the advancement of pharmaceuticals, agrochemicals, and other organic compounds.

Upstream product

• 19924-43-7 3-methoxyphenylacetonitrile 
• 106-93-4 ethylene dibromide 
• 96-49-1 [1,3]-dioxolan-2-one 
• 107-04-0 1-Bromo-2-chloroethane 

Downstream Products

• 940307-96-0 1-(3-hydroxyphenyl)cyclopropanecarbonitrile 
• 1200397-24-5 1-(3-(2,6-dimethylbenzyloxy)phenyl)cyclopropanecarboxylic acid 
• 940307-91-5 1-(3-methoxyphenyl)cyclopropanecarboxamide 
• 74205-29-1 1-(3-methoxyphenyl)cyclopropane-1-carboxylic acid 
• 61492-22-6 (2S,5R,6R)-6-{[1-(3-Methoxy-phenyl)-cyclopropanecarbonyl]-amino}-3,3-dimethyl-7-oxo-4-thia-1-aza-bicyclo[3.2.0]heptane-2-carboxylic acid 

Relevant academic research and scientific papers

Chiral Bidentate Boryl Ligand Enabled Iridium-Catalyzed Enantioselective C(sp3)-H Borylation of Cyclopropanes

We herein report an Ir-catalyzed enantioselective C(sp3)-H borylation of cyclopropanecarboxamides using a chiral bidentate boryl ligand for the first time. A variety of substrates with α-quaternary carbon centers could be compatible in this reaction to provide β-borylated products with good to excellent enantioselectivities. We have also demonstrated that the borylated products can be used as versatile precursors engaging in stereospecific transformations of C-B bonds, including the synthesis of a bioactive compound Levomilnacipran.

Electrophilic Bromolactonization of Cyclopropyl Diesters Using Lewis Basic Chalcogenide Catalysts

An efficient and regioselective electrophilic bromolactonization of cyclopropylmethyl diesters using triphenylphosphine sulfide (Ph3PS) or diphenyl selenide (Ph2Se) as the Lewis basic chalcogenide catalyst has been developed. It was observed that Ph3PS favored the formation of anti-diastereomer and yielded the multi-functional γ-lactones. Interestingly, the diastereoselectivity was reversed when using Ph2Se as a catalyst where the syn-product instead of the anti-product was favored. (Figure presented.).

Enantioselective C-H Functionalization-Addition Sequence Delivers Densely Substituted 3-Azabicyclo[3.1.0]hexanes

An enantioselective C-H functionalization route to perfluoroalkyl-containing 3-azabicyclo[3.1.0]hexanes is disclosed. A modular and bench-stable diazaphospholane ligand enables highly enantioselective Pd(0)-catalyzed cyclopropane C-H functionalization using trifluoroacetimidoyl chlorides as electrophilic partners. In turn, the resulting cyclic ketimine products react smoothly with a broad variety of nucleophiles in one-pot processes enabling the rapid and modular construction of heavily substituted pyrrolidines.

Rhodium-Catalyzed Enantioselective Silylation of Cyclopropyl C?H Bonds

Hydrosilyl ethers, generated in situ by the dehydrogenative silylation of cyclopropylmethanols with diethylsilane, undergo asymmetric, intramolecular silylation of cyclopropyl C?H bonds in high yields and with high enantiomeric excesses in the presence of

DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITORS

Derivatives of purine, 3H-imidazo[4,5-b]pyrimidine and 1H- imidazo[4,5-d]pyrazine of Formula I that inhibit the activity of the diacylglycerol acyltransferase 2 (DGAT2) and their uses in the treatment of diseases linked thereto in animals are described herein.

COMPOUNDS AND METHOD FOR REDUCING URIC ACID

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula (I) or a pharmaceutically acceptable salt thereof. In Formula (I) m is 0, 1, 2, 3 or 4; n is 0 or 1; m + n is not more than 4; t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R6 is hydrogen, methyl or ethyl and R12 is hydrogen or methyl, or R6 is hydroxy and R12 is hydrogen, or R6 is O and R12 is absent, or R6 and R12 together are -CH2CH2-. R7 is hydrogen or alkyl having from 1 to 3 carbon atoms. One of R8 and R9 is alkyl having from 1 to 3 carbon atoms, and the other is hydrogen or alkyl having from 1 to 3 carbon atoms. R10 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms or alkoxy having from 1 to 3 carbon atoms. X is C(O) and r is 0 and t is 0; or X is NH(R11) wherein R11 is hydrogen or alkyl having from 1 to 3 carbon atoms. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula (I) by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl. The uric acid-lowering effects of the Compounds of Formula (I) are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, and cognitive impairment.

FUSED HETEROCYCLIC COMPOUND

The present invention provides a compound represented by the formula: wherein R1ais a hydrogen atom, R2a is a C1-6 alkyl group substituted by a group represented by-NR6a-CO-(CH2) n-SO2

SUBSTITUTED ARYLPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME

The invention relates to substituted arylpyrazolopyridines according to the general formula (I) : in which A, B, D, E, Ra, R1, R2, R3, R4, R5 and q are as defined in the claims, and salts t

Efficient cyclopropanation of active methylene compounds. A serendipitous discovery

Cyclopropanation of active methylene compounds has been achieved in good yields with ethylene carbonate as the cyclopropanating agent in the presence of a simple base.